Why the study?
The prevalence and prognostic impact of the high thrombotic risk criteria proposed by the 2020 ESC NSTE-ACS guidelines were yet to be described, and whether the benefits of prasugrel vs. clopidogrel vary with this risk remained unknown.
Does prasugrel reduce major adverse cardiac events compared to clopidogrel in ACS patients undergoing PCI across different thrombotic risk profiles?
Does prasugrel reduce major adverse cardiac events compared to clopidogrel in ACS patients undergoing PCI across different thrombotic risk profiles?
The 2020 ESC NSTE-ACS guideline definition of high thrombotic risk successfully identifies patients at increased 1-year risk of ischemic events, and prasugrel provides consistent benefit over clopidogrel regardless of this risk status.
Answers are grounded in this paper and cite their sources.
Prasugrel was associated with lower MACE across risk strata in this ACS cohort; leaves open whether findings extend to randomized settings or alter practice.
AIMS: Based on recent clinical data, the 2020 ESC guidelines on non-ST-elevation acute coronary syndrome (NSTE-ACS) suggest to tailor antithrombotic strategy on individual thrombotic risk. Nonetheless, prevalence and prognostic impact of the high thrombotic risk (HTR) criteria proposed are yet to be described. In this analysis from the PROMETHEUS registry, we assessed prevalence and prognostic impact of HTR, defined according to the 2020 ESC NSTE-ACS guidelines, and if the benefits associated with prasugrel vs. clopidogrel vary with thrombotic risk. METHODS AND RESULTS: PROMETHEUS was a multicentre prospective study comparing prasugrel vs. clopidogrel in ACS patients undergoing percutaneous coronary intervention (PCI). Patients were at HTR if presenting with one clinical plus one procedural risk feature. The primary endpoint was major adverse cardiac events (MACE), composite of death, myocardial infarction, stroke, or unplanned revascularization, at 1 year. Adjusted hazard ratio (adjHR) and 95% confidence intervals (CIs) were calculated with propensity score stratification and multivariable Cox regression. Among 16 065 patients, 4293 (26.7%) were at HTR and 11 772 (73.3%) at low-to-moderate thrombotic risk. The HTR conferred increased incidence of MACE (23.3 vs. 13.6%, HR 1.85, 95% CI 1.71-2.00, P < 0.001) and its single components. Prasugrel was prescribed in patients with less comorbidities and risk factors and was associated with reduced risk of MACE (HTR: adjHR 0.83, 95% CI 0.68-1.02; low-to-moderate risk: adjHR 0.75, 95% CI 0.64-0.88; pinteraction = 0.32). CONCLUSION: High thrombotic risk, as defined by the 2020 ESC NSTE-ACS guidelines, is highly prevalent among ACS patients undergoing PCI. The HTR definition had a strong prognostic impact, as it successfully identified patients at increased 1 year risk of ischaemic events.
No takes yet. Share an insight, caveat, or question.
Chiarito et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: